Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy ...

Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings On track for full data read out in the first half of 2026 Discovery and preclinical data on O3R-5671 selected for ...

Esther leaves us with no false promises, no hacks, no cheats. It starts with a breath. Not the triumphant kind — not yet. This one is shaky. It trembles inside the ribs of a 12-year-old seated in a ...

AURORA, Colo., Oct. 1, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, today announced that a human ...

Around twenty years ago, when I was a graduate student in English, I taught a class in a special observation room at my university’s teaching center. My students and I sat around a long oval table ...

A total of 10,644 candidates have passed the preliminary examination of the 47th Bangladesh Civil Service (BCS). More than 374,000 applicants had registered to sit the test. The results were published ...

Kannur, Kerala: Kerala Police and the Intelligence agencies launched a probe after a ninth-grade student allegedly wrote the names of international terrorist organisations and sketched weapons in a ...

SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming ...

MUNICH--(BUSINESS WIRE)--Tubulis today announced that its late-breaking abstract covering first clinical data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for oral ...

Second oral presentation will provide updated data from GDFATHER-01 trial demonstrating deep and durable remissions in heavily pretreated patients CatalYm, a world-leader in neutralizing GDF-15 in ...

Tubulis’ lead antibody-drug conjugate (ADC) TUB-040 is directed against NaPi2b, an antigen highly overexpressed in ovarian cancer and lung adenocarcinoma. It consists of an IgG1 antibody targeting ...